Drug Delivery's Consolidationist Argument
Recent dealmaking among drug delivery firms indicates that some companies, at least, see a value to offering a breadth of technology pharmaceutical clients.
You may also be interested in...
The great recognition of the drug delivery industry is that technologies don't sell--only drugs do. The result: drug delivery start-ups today must be drug companies, selling their best shot at using their technologies to create highly differentiated drug products. To do so, start-ups are pursuing two different visions. On the one hand are those who try to do as little as possible to the underlying molecule, thereby reducing risk and cost while relying on their system for product differentiation. On the other are those who believe that only important modifications to the molecule, or at least a deep understanding of the biology underlying a specific compound's therapeutic role, permit fundamental improvements in treatment.
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.